Merck commits nearly $2 billion to acquire oral lipid-lowering drug from Chinese biotech firm, aiming to expand its cardiovascular portfolio and enhance global market reach, BioSpace reports.
Browsing: lipid-lowering
Merck commits nearly $2 billion to acquire oral lipid-lowering drug from Chinese biotech firm, aiming to expand its cardiovascular portfolio and enhance global market reach, BioSpace reports.